Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

Publication date: Available online 30 October 2020Source: The Lancet Diabetes & EndocrinologyAuthor(s): Karine Clément, Erica van den Akker, Jesús Argente, Allison Bahm, Wendy K Chung, Hillori Connors, Kathleen De Waele, I Sadaf Farooqi, Julie Gonneau-Lejeune, Gregory Gordon, Katja Kohlsdorf, Christine Poitou, Lia Puder, James Swain, Murray Stewart, Guojun Yuan, Martin Wabitsch, Peter Kühnen, Patricia Pigeon-Kherchiche, Anna Flaus-Furmaniuk
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research